-+ 0.00%
-+ 0.00%
-+ 0.00%

Akari ASCO abstract shows AKTX-101 synergy with KRAS inhibitor in pancreatic cancer

PUBT·04/21/2026 13:11:52
Listen to the news
Akari ASCO abstract shows AKTX-101 synergy with KRAS inhibitor in pancreatic cancer
  • Akari Therapeutics disclosed acceptance of an ASCO 2026 abstract on preclinical combination work supporting its AKTX-101 antibody-drug conjugate in KRAS-mutant pancreatic cancer.
  • Results have not yet been presented; full abstract will be published online May 21, 2026 at 5:00 PM ET.
  • Study outcome points to improved anti-tumor activity when AKTX-101 is paired with a KRAS inhibitor, supporting a potential combination strategy in hard-to-treat tumors.
  • Update broadens perceived commercial and development scope for AKTX-101 beyond Akari’s current Phase 1 plan.
  • Akari reiterated plans to start first-in-human Phase 1 development for AKTX-101 in late 2026 or early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.